21500
investors
Capital Cell is a Barcelona-based equity crowdfunding platform devoted entirely to biotech and health companies - Europe's longest-running specialist of its kind, operating since around 2015 and authorised by Spain's markets regulator CNMV under EU crowdfunding rules (licence no. 12, November 2023), with a passport across 26 European countries.
Investors buy, from EUR 500, stakes in early-stage drug, diagnostics and medical-device companies - around EUR 82 million invested through the platform into 144 companies over 150 published funding rounds (the EUR 162 million it headlines includes money committed by co-investors alongside the crowd). Each deal passes a six-stage screen including review by a 3,500-strong expert network and a mandatory professional lead investor who sets the price; only about 3% of applicants are listed.
What you usually hold is not a share in your own name but a certificate from a Dutch holding foundation (a STAK) that owns the shares and votes the whole block after polling investors.
Money is held in escrow at a regulated payment institution until a round completes, and refunded in full if it fails.
Be clear about the nature of the asset: these are illiquid stakes in companies that will need many further funding rounds - typically shrinking early investors' percentage - over seven to ten years or more, with no promised end date.
The platform's own record shows both sides plainly: it marks the portfolio at 2.7 times cost on paper, while 14 of the 150 rounds it has published are labelled write-offs and only four carry an exit label.
Investing is free; Capital Cell keeps 8% of any profit when you eventually sell, and companies pay about 8% of what they raise.
License / Regulation: ECSPR crowdfunding service provider, CNMV | Licence 12 |
Every candidate passes six gates: in-house analysis of the business plan, patents and funding roadmap; review by the BioExpert Network of 3,500-plus scientists and industry specialists (about a third of companies fail here); a mandatory professional lead investor who has done independent due diligence and validated the share price; legal and financial due diligence; an independent regulatory and market-access review by Alira Health; and a patent freedom-to-operate check by European patent agents. Only about 3 in 100 applicants get listed. Understand the limit: the screen validates the science and the price of one round - it cannot underwrite clinical trial results, future funding terms or whether an exit ever happens, and 14 approved rounds are now written off.
Founder Daniel Oliver, a biologist turned financier, is the sole registered administrator of the Spanish licensed entity. The CEO is Julien Gillet-Daubin, with 20 years in high-tech management, alongside country directors for Spain (Mariona Vidal-Picamoles, biosciences background) and Italy (Riccardo Aimerito, lawyer), a Cambridge genetics PhD as investment manager, a bioengineering PhD as portfolio manager, and named legal, technology and marketing leads. The team's shape reflects the platform's shift from a Spanish operation to a pan-European one - its 2026 deal flow is dominated by French and Swiss companies. Note the concentrated formal control: a single sole administrator runs the regulated entity.
After a round closes, the Dutch STAK foundation administers your holding free of charge: it keeps the register, issues certificates and, when a shareholder decision arises, polls investors electronically and casts the entire block's vote by majority of respondents - binding non-voters and dissenters alike. Companies routinely return for further rounds (one raised on the platform four times in five years), shrinking earlier investors' stakes; protection is limited to case-by-case anti-dilution clauses, tag-along rights, and drag-along terms that can force you to sell. There is no published reporting standard, and the loudest investor complaints are precisely about silence after investment - no updates, ignored meeting requests, missing documents.
Joining, investing, deposits and the annual administration of your holding are free; card fees and notary costs are borne by the company raising money. Capital Cell earns from both sides on success: companies pay about 8% of a completed round, and investors pay an 8% share of profits when they eventually sell - nothing if there is no profit. Selling early on the internal noticeboard costs 8% of the transaction. Spanish taxpayers may qualify for a 50% income-tax deduction on amounts invested in young companies - but check carefully: the platform's usual Dutch STAK structure may conflict with that deduction's requirement of direct investment, and Capital Cell does not resolve the point publicly.
No scandal, sanction or fraud allegation was found, and no CNMV measure exists against the platform. A Trustpilot profile exists. The substantive criticism lives on the Spanish investor forum Rankia, in a thread running since 2017: investors describe long information blackouts ('a long time without any new information', June 2026) and the Bionure saga - holders moved into a French vehicle in 2025 report receiving no share certificates or shareholder list, a formally requested meeting ignored, and template legal demands circulating among investors - plus general doubts about whether 'you are sold something of value or just little papers'. A separate finding: Capital Cell's abandoned UK website still displays a live-looking FCA promotion notice for a UK company that was dissolved (solvently) in June 2025 - stale and potentially misleading to UK visitors, though not fraudulent. The same thread also carries positive experiences, including one company sold to a venture fund at a profit.
Plan for seven to ten years or more, possibly never. The platform's marketing says three to six years; its own oldest cohort says otherwise - the 2017 Bionure investors are nine years in, through two restructurings, with the underlying asset sale not closing before 2027. An acquisition or stock-market listing does not automatically pay you: the GoodGut trade sale (2021) never disclosed what crowd investors received, and the Vytrus listing only rewarded those who sold shares themselves. An 'exit' on this platform has usually meant a corporate event, not cash in your account.
It is a paper mark: the value of shares nobody can currently sell, set by what later investors paid in subsequent funding rounds. Capital Cell publishes no date, no method and no definition for it. Two things put it in perspective. Concentration: remove the three best companies and the multiple falls to 1.14x, so a typical ten-company portfolio may hold none of the winners. And youth: the average euro on this platform has been invested about three and a half years, against an exit horizon of seven to ten years, so most of the portfolio has neither failed nor succeeded yet. The write-offs are the part already settled, 14 of the 92 rounds old enough to judge. Spanish investors should also note the platform's shift: 2026 deals are mostly French, Swiss and British companies, to which the Spanish startup tax deduction generally will not apply.
